MEDINET AND MAXCYTE INITIATE COLLABORATION FOR NOVEL CANCER IMMUNO-CELL THERAPY

MaxCyte, Inc. and Medinet Co., Ltd. announced the signing of a collaboration agreement. Under the agreement MaxCyte will optimize its proprietary cell loading system for the development of Medinet's novel cancer immuno-cell therapy and implementation in a closed-system manufacturing process at Medinet's four cell processing centers in Japan. MaxCyte and Medinet have also agreed to key terms for a commercial license to MaxCyte's cell loading system to support clinical studies and commercialization of Medinet's immunotherapy product. Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=4805129)